Robert Renninger's Insider Trades & SAST Disclosures
Robert Renninger's most recent trade in Athira Pharma Inc was a trade of 73,350 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 3, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Renninger.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 73,350 | 73,350 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 73,350 | 73,350 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 58,500 | 58,500 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Robert Renninger | SVP, Finance and Accounting | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 39,000 | 39,000 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 12,359 | 92,605 | - | 0 | Common Stock | |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 12,359 | 24,718 | - | - | Restricted Stock Units | |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.55 per share. | 31 Dec 2024 | 3,651 | 80,246 | - | 0.5 | 2,008 | Common Stock |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Sale of securities on an exchange or to another person at price $ 0.56 per share. | 31 Dec 2024 | 2,881 | 89,724 | - | 0.6 | 1,619 | Common Stock |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 37,077 | 37,077 | - | - | Stock Option (Right to Buy) | |
| Athira Pharma Inc | Robert Renninger | VP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2024 | 37,077 | 37,077 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges